Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-β.

Shahbaz S, Bozorgmehr N, Koleva P, Namdar A, Jovel J, Fava RA, Elahi S.

PLoS Biol. 2018 Dec 14;16(12):e2006649. doi: 10.1371/journal.pbio.2006649. eCollection 2018 Dec.

2.

VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.

Ceeraz S, Eszterhas SK, Sergent PA, Armstrong DA, Ashare A, Broughton T, Wang L, Pechenick D, Burns CM, Noelle RJ, Vincenti MP, Fava RA.

Arthritis Res Ther. 2017 Dec 8;19(1):270. doi: 10.1186/s13075-017-1474-y.

3.

Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome.

Fava RA, Kennedy SM, Wood SG, Bolstad AI, Bienkowska J, Papandile A, Kelly JA, Mavragani CP, Gatumu M, Skarstein K, Browning JL.

Arthritis Res Ther. 2011;13(6):R182. doi: 10.1186/ar3507. Epub 2011 Nov 1.

4.

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.

Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu LF, Gondek D, Wang Y, Fava RA, Fiser A, Almo S, Noelle RJ.

J Exp Med. 2011 Mar 14;208(3):577-92. doi: 10.1084/jem.20100619. Epub 2011 Mar 7.

5.

LTBR-pathway in Sjogren's syndrome: CXCL13 levels and B-cell-enriched ectopic lymphoid aggregates in NOD mouse lacrimal glands are dependent on LTBR.

Fava RA, Browning JL, Gatumu M, Skarstein K, Bolstad AI.

Adv Exp Med Biol. 2011;691:383-90. doi: 10.1007/978-1-4419-6612-4_39. No abstract available.

PMID:
21153342
6.

Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10.

Kelly JA, Griffin ME, Fava RA, Wood SG, Bessette KA, Miller ER, Huber SA, Binder CJ, Witztum JL, Morganelli PM.

Cardiovasc Res. 2010 Jan 1;85(1):224-31. doi: 10.1093/cvr/cvp300.

7.

Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice.

Gatumu MK, Skarstein K, Papandile A, Browning JL, Fava RA, Bolstad AI.

Arthritis Res Ther. 2009;11(1):R24. doi: 10.1186/ar2617. Epub 2009 Feb 18.

8.

A Stat5b transgene is capable of inducing CD8+ lymphoblastic lymphoma in the absence of normal TCR/MHC signaling.

Bessette K, Lang ML, Fava RA, Grundy M, Heinen J, Horne L, Spolski R, Al-Shami A, Morse HC 3rd, Leonard WJ, Kelly JA.

Blood. 2008 Jan 1;111(1):344-50. Epub 2007 Sep 21.

9.

The synthetic triterpenoid TP-222 inhibits RANKL stimulation of osteoclastogenesis and matrix metalloproteinase-9 expression.

Fava RA, Elliott S, Raymond L, Mollmark J, Hays E, Honda T, Gribble GW, Sporn MB, Vincenti MP.

J Rheumatol. 2007 May;34(5):1058-68. Epub 2007 Mar 15.

PMID:
17361985
10.

Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function.

Browning JL, Allaire N, Ngam-Ek A, Notidis E, Hunt J, Perrin S, Fava RA.

Immunity. 2005 Nov;23(5):539-50.

11.

A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis.

Fava RA, Notidis E, Hunt J, Szanya V, Ratcliffe N, Ngam-Ek A, De Fougerolles AR, Sprague A, Browning JL.

J Immunol. 2003 Jul 1;171(1):115-26.

12.

Does vascular endothelial growth factor play a role in interleukin-6 receptor antagonist therapy for rheumatoid arthritis?

Gentiletti J, Fava RA.

Arthritis Rheum. 2003 Jun;48(6):1471-4. Review. No abstract available.

13.

Analysis of the function, expression, and subcellular distribution of human tristetraprolin.

Brooks SA, Connolly JE, Diegel RJ, Fava RA, Rigby WF.

Arthritis Rheum. 2002 May;46(5):1362-70.

14.
15.

Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies.

Paleolog EM, Fava RA.

Springer Semin Immunopathol. 1998;20(1-2):73-94. No abstract available.

PMID:
9836370
16.

Collagen-induced arthritis as a model of rheumatoid arthritis.

Durie FH, Fava RA, Noelle RJ.

Clin Immunol Immunopathol. 1994 Oct;73(1):11-8. Review.

PMID:
7923907
17.

Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.

Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF.

J Exp Med. 1994 Jul 1;180(1):341-6.

18.
20.

Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.

Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ.

Science. 1993 Sep 3;261(5126):1328-30.

PMID:
7689748
21.
22.

Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia.

Fava RA, Olsen NJ, Postlethwaite AE, Broadley KN, Davidson JM, Nanney LB, Lucas C, Townes AS.

J Exp Med. 1991 May 1;173(5):1121-32.

23.

Synthesis of transforming growth factor-beta 1 by megakaryocytes and its localization to megakaryocyte and platelet alpha-granules.

Fava RA, Casey TT, Wilcox J, Pelton RW, Moses HL, Nanney LB.

Blood. 1990 Nov 15;76(10):1946-55.

PMID:
2242422
24.

Lipocortin I (p35) is abundant in a restricted number of differentiated cell types in adult organs.

Fava RA, McKanna J, Cohen S.

J Cell Physiol. 1989 Nov;141(2):284-93.

PMID:
2530241
25.
26.

The role of epidermal growth factor in skin diseases.

King LE Jr, Ellis DL, Gates RE, Inman WH, Stoscheck CM, Fava RA, Nanney LB.

Am J Med Sci. 1988 Sep;296(3):154-8. Review. No abstract available.

PMID:
3052058
27.
28.

Fibronectin-associated transforming growth factor.

Fava RA, McClure DB.

J Cell Physiol. 1987 May;131(2):184-9.

PMID:
3495542
29.
31.
32.

Supplemental Content

Support Center